NASDAQ: AVXL

Daniel Weintraub, MD

Scientific Advisor

Dr. Weintraub is a professor of psychiatry at Perelman School of Medicine at the University of Pennsylvania in Philadelphia. He is a professor of psychiatry and neurology at Penn and a psychiatrist at the Parkinson’s Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical Center. A geriatric psychiatrist, he conducts clinical research on the psychiatric and cognitive complications of Parkinson’s disease and is the author of more than 100 journal articles, reviews, and book chapters. Dr. Weintraub completed an NIMH Career Development Award titled “Depression Diagnosis and Treatment in Parkinson’s Disease” and has been PI on grants from the VA, Penn, The Michael J. Fox Foundation for Parkinson’s Research, and several industry-sponsored studies. He is also the current clinical core leader of the Penn Udall Center, which focuses on cognition in Parkinson’s disease. Dr. Weintraub is Associate Editor for Movement Disorders journal, was formerly on the Executive Committee of the Parkinson Study Group (PSG), and has been a member of four Movement Disorder Society (MDS) task forces to revise and make recommendations for the assessment of cognitive and psychiatric symptoms in Parkinson’s disease and was chair of the Psychiatry Subgroup of the NINDS Common Data Elements (CDE) project.

You are about to leave our website

By clicking “Continue,” you acknowledge that you are leaving the Anavex Life Sciences website and will be redirected to a third-party website operated by NASDAQ or its affiliates.

Anavex Life Sciences does not own, control, maintain, or endorse the content on third-party websites and is not responsible for their accuracy, completeness, or reliability. Any information available through this link is provided by third parties and does not represent the views, opinions, forecasts, or predictions of Anavex Life Sciences or its management.

The linked content is provided for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should rely on their own independent judgment and consult professional advisors before making any investment decisions.